Commonwealth of Massachusetts
MassHealth Drug Utilization Review Program
P.O. Box 2586, Worcester, MA 01613-2586
Fax: (877) 208-7428 **Phone:** (800) 745-7318

Glaucoma Agents Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist.**

Member information

Last name ______________________________ First name ____________________________ MI __________

MassHealth member ID # _________________ Date of birth ____

Gender (Check one.) ☐ F ☐ M Member's place of residence ☐ home ☐ nursing facility

Medication information

Medication requested

☐ Azopt (brinzolamide)
☐ bimatoprost 0.03%
☐ dorzolamide/timolol preservative free
☐ Lumigan (bimatoprost 0.01%)
☐ Rhopressa (netarsudil)
☐ Rocklatan (netarsudil/latanoprost)
☐ Simbrinza (brinzolamide/brimonidine)
☐ timolol ophthalmic gel forming solution
☐ Timoptic Ocudose (timolol ophthalmic unit dose solution)
☐ Vyzulta (latanoprostene)
☐ Xelpros (latanoprost emulsion)
☐ Zioptan (tafluprost)

Indication (Check all that apply.)

☐ Open-angle glaucoma ☐ Ocular hypertension ☐ Other __________________________

Dose and frequency of medication requested ____

Section I. Please complete for timolol ophthalmic gel forming solution and Timoptic Ocudose requests.

Has the member had a trial with an ophthalmic timolol formulation that is available without PA?

☐ Yes ☐ No. Please provide clinical rationale for not using an ophthalmic timolol formulation that is available without PA. ____

____

Section II. Please complete for Azopt requests.

Has the member had a trial with dorzolamide 2%?

☐ Yes ☐ No. Please provide clinical rationale for not using dorzolamide 2%. __________________________

____

Section III. Please complete for dorzolamide/timolol preservative free and Xelpros requests.

Has the member experienced sensitivity to benzalkonium chloride or any other preservatives used in ophthalmic preparations?

☐ Yes ☐ No. Please provide clinical rationale for the use of the requested formulation instead of the respective formulation that is available without PA. ____

____

Section IV. Please complete for Rhopressa and Rocklatan requests.

1. Has the member had a trial of combination therapy with a prostaglandin analog and an ophthalmic beta-blocker?
   ☐ Yes. Please list the drug names, dates/duration of use and outcomes below.*
   ☐ No. Please provide clinical rationale for not using combination therapy with a prostaglandin analog and an ophthalmic beta-blocker. ____
2. Does the member have a contraindication to ophthalmic beta-blockers?
   ☐ Yes. Please describe. ____ ☐ No
   If yes, has the member had a trial of combination therapy with a prostaglandin analog and either an ophthalmic alpha-2 adrenergic agonist, parasympathomimetic, or carbonic anhydrase inhibitor?
   ☐ Yes. Please list the drug names, dates/duration of use and outcomes below.* ☐ No
3. For Rhopressa, does the member have a contraindication to prostaglandin analogs?
   ☐ Yes. Please describe. ____ ☐ No
   If yes, has the member had a trial of combination therapy with an ophthalmic beta-blocker and either an ophthalmic alpha-2 adrenergic agonist, parasympathomimetic, or carbonic anhydrase inhibitor?
   ☐ Yes. Please list the drug names, dates/duration of use and outcomes below.* ☐ No
4. For Rocklatan, please describe the medical necessity for use of the combination product over the separately available ingredients. ____

   ____

   Please provide details for the previous trials.
   Drug ______________ Dates/duration __________ ☐ Adverse reaction ☐ Inadequate response ☐ Other
   Briefly describe details of adverse reaction, inadequate response, or other.

   ____

   Drug ______________ Dates/duration __________ ☐ Adverse reaction ☐ Inadequate response ☐ Other
   Briefly describe details of adverse reaction, inadequate response, or other.

   ____

**Please attach a letter documenting additional trials as necessary.*

Section V. Please complete for Simbrinza requests.

Has the member had a trial with a carbonic anhydrase inhibitor and an ophthalmic brimonidine product?
☐ Yes ☐ No. Please provide clinical rationale for not using a carbonic anhydrase inhibitor and an ophthalmic brimonidine product. ____

____

Section VI. Please complete for Vyzulta requests.

Has the member had a trial of combination therapy with latanoprost solution and an ophthalmic beta-blocker?
☐ Yes ☐ No. Please provide clinical rationale for not using combination therapy with latanoprost solution and an ophthalmic beta-blocker. ____

____

Section VII. Please complete for Zioptan requests.

1. Has the member had a trial with latanoprost solution?
   ☐ Yes ☐ No. Please provide clinical rationale for not using latanoprost solution. ____________________

   ____

over

2. Has the member had a trial with Xelpros?
☐ Yes ☐ No. Please provide clinical rationale for not using Xelpros. ______________________________
____

Section VIII. Please complete for all requests for non-preferred drug products if one or more preferred drug products have been designated for this class of drugs.

If one or more preferred drug products have been designated for this class of drugs, and if you are requesting PA for a non-preferred drug product, please provide medical necessity for prescribing the non-preferred drug product rather than the preferred drug product.

____
____
____

Prescriber information

Last name* ______________________________ First name* ______________________ MI __________
NPI* __________________________________ Individual MH Provider ID __________________________
DEA No. ________________________________ Office Contact Name ____________________________
Address _________________________________ City _______________ State ________ Zip ___________
E-mail address ____
Telephone No.* ___________________________ Fax No.* ____
** Required*

Prescribing provider's attestation, signature, and date

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature (Signature and date stamps, or the signature of anyone other than the provider, are not acceptable.)

Signature required ____

Printed name of prescribing provider _____________________________ Date _______________________